News und Analysen

Dividends never go out of style, but some dividend stocks can. That's how some investors might feel about Pfizer (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY) these days. Both companies have

Dividends never go out of style, but some dividend stocks can. That's how some investors might feel about Pfizer (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY) these days. Both companies have

Amgen (NASDAQ: AMGN) is one of the largest drug manufacturers in the world, with a market cap of more than $150 billion. It pays a dividend, has been growing steadily over the years, and has many

Amgen (NASDAQ: AMGN) is one of the largest drug manufacturers in the world, with a market cap of more than $150 billion. It pays a dividend, has been growing steadily over the years, and has many

Amgen (NASDAQ: AMGN) is one of the largest drug manufacturers in the world, with a market cap of more than $150 billion. It pays a dividend, has been growing steadily over the years, and has many

Wall Street analysts are quite bullish about Intellia Therapeutics (NASDAQ: NTLA) stock. On average, they're estimating that it'll rise by around 157% within the next 12 months. In the context of

Shares of Trupanion (NASDAQ: TRUP) plunged 35% on Friday after an accounting controls warning overshadowed better-than-expected preliminary fourth-quarter results from the pet insurance provider.

Shares of Sarepta Therapeutics (NASDAQ: SRPT) were soaring 10.4% higher as of 10:58 a.m. ET on Friday. The big gain came after the biopharmaceutical company announced that the U.S. Food and Drug

Equity markets can be highly volatile in the short run. Where the S&P 500 might land in the next six months is anyone's guess. However, over a decade, major indexes tend to move steadily in the

Three otherwise innocuous words -- reverse stock split -- can cause much disappointment and even sow panic in an investor community. Shareholders of clinical-stage biotech Agenus (NASDAQ: AGEN)

Many people make it a New Year's resolution to start investing -- a laudable goal. The good news is that doing so doesn't require millions of dollars in the bank. Even with $500, a relatively modest

IRAs and 401(k)s are great plans in which to save for retirement, thanks to the tax breaks involved. With a traditional IRA or 401(k), your contributions go into your account tax-free. With a Roth

I've been a big fan of Vertex Pharmaceuticals (NASDAQ: VRTX), and the biotech stock has made me a lot of money throughout the years. Vertex continues to enjoy a virtual monopoly in treating cystic

I've been a big fan of Vertex Pharmaceuticals (NASDAQ: VRTX), and the biotech stock has made me a lot of money throughout the years. Vertex continues to enjoy a virtual monopoly in treating cystic

I've been a big fan of Vertex Pharmaceuticals (NASDAQ: VRTX), and the biotech stock has made me a lot of money throughout the years. Vertex continues to enjoy a virtual monopoly in treating cystic

After a brutal three-year period that saw its shares collapse by 99%, any remaining longtime shareholders of Novavax (NASDAQ: NVAX) are doubtlessly eager for the biotech to finally step out of the

Shares of QuidelOrtho (NASDAQ: QDEL) were crashing 31.4% lower as of 11:30 a.m. ET on Wednesday. The huge decline came after the in vitro diagnostics company announced its 2023 full-year and

Healthcare is something that tends to catch retirees off guard -- namely because of how expensive it has the potential to be. That's why it's so important to save for healthcare ahead of retirement

Amgen (NASDAQ: AMGN) is well on its way to producing a medicine for obesity that could one day rival the blockbuster weight-loss drugs like Wegovy and Zepbound made by the segment's monarchs, Novo

Amgen (NASDAQ: AMGN) is well on its way to producing a medicine for obesity that could one day rival the blockbuster weight-loss drugs like Wegovy and Zepbound made by the segment's monarchs, Novo

Amgen (NASDAQ: AMGN) is well on its way to producing a medicine for obesity that could one day rival the blockbuster weight-loss drugs like Wegovy and Zepbound made by the segment's monarchs, Novo

Image source: The Motley Fool.

Zoetis (NYSE: ZTS)Q4 2023 Earnings CallFeb 13, 2024, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

Biogen (NASDAQ: BIIB)Q4 2023 Earnings CallFeb 13, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

Biogen (NASDAQ: BIIB)Q4 2023 Earnings CallFeb 13, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com